Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03824327 · ClinicalTrials.gov registry record · Phase 1
Papaverine and Stereotactic Body Radiotherapy (SBRT) for Non Small Cell Lung Cancer (NSCLC) or Lung Metastases
A Phase 1 study of Lung Non-Small Cell Carcinoma, sponsored by Ohio State University Comprehensive Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT03824327: Active Phase 1 study of Lung Non-Small Cell Carcinoma, sponsored by Ohio State University Comprehensive Cancer Center.
NCT03824327 is a Phase 1 study of Lung Non-Small Cell Carcinoma that is active but no longer recruiting, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 19 participants, below the 160-participant average among 47 other Lung Non-Small Cell Carcinoma trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03824327, a Phase 1 study of Lung Non-Small Cell Carcinoma, is active but no longer recruiting, sponsored by Ohio State University Comprehensive Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies the side effects and how well papaverine hydrochloride and stereotactic radiation therapy body (SBRT) work in treating patients with non-small cell lung cancer. Papaverine hydrochloride may help radiation therapy work better by making tumor cells more sensitive to the radiation therapy. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving papaverine hydrochloride with SBRT may work in treating patients with non-small cell lung cancer.
Primary Outcome
Will employ the Bayesian optimal interval (BOIN) design to find the MTD.
Conditions Studied
Interventions
- RADIATION Stereotactic Body Radiation Therapy
- PROCEDURE Blood Oxygen Level Dependent Imaging
- DRUG Papaverine Hydrochloride
Study Locations (1)
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2019-02-07 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
What the registry record for NCT03824327 still lists
NCT03824327 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 160-participant average among 47 other Lung Non-Small Cell Carcinoma trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Lung Non-Small Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Stereotactic Body Radiation Therapy is the first listed.
NCT03824327 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT03824327 about?
NCT03824327 is a clinical study titled "Papaverine and Stereotactic Body Radiotherapy (SBRT) for Non Small Cell Lung Cancer (NSCLC) or Lung Metastases". This phase I trial studies the side effects and how well papaverine hydrochloride and stereotactic radiation therapy body (SBRT) work in treating patients with non-small cell lung cancer. Papaverine hydrochloride may help radiation therapy work better by making tumor cells more sensitive to the radi...
What is the current status of trial NCT03824327?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2019-02-07. Estimated completion is 2027-12-31.
What conditions does trial NCT03824327 study?
This clinical trial studies the following conditions: Lung Non-Small Cell Carcinoma.
What interventions are being tested in trial NCT03824327?
The interventions under investigation include: Stereotactic Body Radiation Therapy (RADIATION), Blood Oxygen Level Dependent Imaging (PROCEDURE), Papaverine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT03824327?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03824327 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Non-Small Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03824327's enrollment target sits among peer trials
19 41st of 47 higher than 7 of 47 other Lung Non-Small Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Non-Small Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gilteritinib for the Treatment of ALK NSCLC
RECRUITING · Phase 1
-
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
RECRUITING · Phase 1
-
CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer
ACTIVE NOT RECRUITING · Phase 1
-
CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma
ACTIVE NOT RECRUITING · Phase 1
-
Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI